PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK NHS PERSPECTIVE

@article{Botteman2005PCN5BI,
  title={PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK NHS PERSPECTIVE},
  author={M. Botteman and M. Aapro and J. Stephens and J. Hay and J. Brandman},
  journal={Value in Health},
  year={2005},
  volume={8},
  pages={345}
}
PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK NHS PERSPECTIVE Botteman M,Aapro M, Stephens J, Hay JW, Brandman J PharMerit North America, Bethesda, MD, USA; Clinique de Genolier, Genolier, Switzerland; University of Southern California, Los Angeles, CA, USA; Novartis Pharmaceutical Corporation, Florham Park, NJ, USA OBJECTIVE… Expand